alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 243 studies with an author at Indiana University School of Medicine (page 3 of 10) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 243 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Annals of Neurology 2025-09-22

MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non-Hispanic Black. 5 key findings →

Design: longitudinal study Participants: 1,883 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature medicine 2022-08-11

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology: Clinical Practice 2026-05-13

Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. 4 key findings →

Design: phase-3-trial Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature communications 2024-11-18

Disease-modifying therapies for Alzheimer's disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. 2 key findings →

Design: cross-sectional Participants: 567 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Alzheimer disease and associated disorders 2003-04-01

Advances in genetic research have provided a basis for susceptibility testing for Alzheimer disease (AD). 2 key findings →

Design: randomized controlled trial Participants: 160 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Targeting Functional Decline in Alzheimer Disease: A Randomized Trial

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Annals of internal medicine 2016-11-22

The authors could not definitively demonstrate whether the addition of 2 years of in-home occupational therapy to a collaborative care management model slowed the rate of functional decline among persons with Alzheimer disease. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2016-06-01

The use of AC medication was associated with increased brain atrophy and dysfunction and clinical decline. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Alzheimer s & Dementia 2025-04-01

While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. 5 key findings →

Design: longitudinal study Participants: 337 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA network open 2025-05-01

Lobar CMB counts and the presence of CAA were associated with downstream AD plasma biomarkers, including p-tau217 (β = 0.12 [95% CI, 0.05-0.18] and 0.29 [95% CI, 0.12-0.47], respectively), GFAP (β = 0.07 [95% CI, 0.03-0.12] and 0.20 [95% CI, 0.09-0.31], respectively), and NfL (β = 0.07 [95% CI, 0.03-0.11] and 0.16 [95% CI, 0.06-0.25], respectively) with and without the mediation of Aβ uptake on PET (indirect effect: lobar CMBs-p-tau217, 59.8% [β = 0.07 (95% CI, 0.03-0.11)]; lobar CMBs-GFAP, 49.3% [β = 0.04 (95% CI, 0.01-0.06)]; lobar CMBs-NfL, 20.9% [β = 0.01 (95% CI, 0.01-0.03)]; CAA-p-tau217, 50.9% [β = 0.15 (95% CI, 0.06-0.24)]; CAA-GFAP, 39.2% [β = 0.08 (95% CI, 0.03-0.13)]; CAA-NfL, 19.2% [β = 0.03 (95% CI, 0.01-0.05)]). 4 key findings →

Design: cohort study Participants: 1,708 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2006-01-01

There was a significant interaction between cholesterol, APOE-epsilon4, and the risk of Alzheimer disease (AD) in the Yoruba, a population that has lower cholesterol levels and lower incidence rates of AD compared to African Americans. 4 key findings →

Design: longitudinal study Participants: 1,075 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Archives of neurology 2001-03-01

Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. 3 key findings →

Design: open-label trial Participants: 187 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-07-01

In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. 2 key findings →

Design: randomized controlled trial Participants: 185 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Blood Pressure and Cognitive Decline Over 8 Years in Middle-Aged and Older Black and White Americans

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Hypertension (Dallas, Tex. : 1979) 2019-02-01

Although the association between high blood pressure (BP), particularly in midlife, and late-life dementia is known, less is known about variations by race and sex. 5 key findings →

Design: cohort study Participants: 2,003 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2007-12-07

Multiple system tauopathy with presenile dementia (MSTD) is an inherited disease caused by a (g) to (a) transition at position +3 in intron 10 of Tau. 1 key finding →

Design: longitudinal study Participants: 21 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neuropathology and applied neurobiology 2015-02-01

Hereditary frontotemporal dementia associated with mutations in the microtubule-associated protein tau gene (MAPT) is a protean disorder. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed